Medpace tumbles after bookings disappoint
** Medpace's MEDP.O shares down 13.6% premarket to three-mth low $377.91 after clinical contract research organization's bookings miss expectations
** Co late Mon reported Q2 new business awards decreased 4% yr/yr for net book-to-bill ratio (number of orders received to those fulfilled) of 1.04x
** TD Cowen, which rates MEDP "buy", pointed out that consensus called for book-to-bill ratio of 1.23x
** While unclear what drove bookings weakness, some explanations might include higher cancellations, lower win rates, and/or lower pass-throughs, TD Cowen said in note to clients
** MEDP said Q2 rev grew 14.6% to $528.1 mln and posted adj EPS of $2.75. LSEG estimates were $528.6 mln and $2.54
** Co lowered FY rev guidance to $2.13-$2.18 bln vs prior forecast of $2.15-$2.2 bln, though hiked profit guidance to $11.24-$11.93 from previous outlook of $10.79-$11.47
** In comparison, peer IQVIA IQV.N on Mon reported its Q2 book-to-bill ratio rose to 1.27x from 1.23x in Q1. IQV shares on Mon closed up ~9%
** Through Mon close, MEDP shares up ~43% YTD and up nearly 80% over the past 12 months
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
</body></html>免責聲明: XM Group提供線上交易平台的登入和執行服務，允許個人查看和/或使用網站所提供的內容，但不進行任何更改或擴展其服務和訪問權限，並受以下條款與條例約束：（i）條款與條例；（ii）風險提示；（iii）完全免責聲明。網站內部所提供的所有資訊，僅限於一般資訊用途。請注意，我們所有的線上交易平台內容並不構成，也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。
所有缐上交易平台所發佈的資料，僅適用於教育/資訊類用途，不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議，或是交易價格紀錄，或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。
本網站的所有XM和第三方所提供的内容，包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接，皆爲‘按原狀’，並作爲一般市場評論所提供，而非投資建議。請理解和接受，所有被歸類為投資研究範圍的相關内容，並非爲了促進投資研究獨立性，而根據法律要求所編寫，而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊，相關詳情請點擊 這裡查看。
